Sanofi

In News

Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’ - Fierce Biotech

Fierce Biotech - Aug 05, 2026

Novavax tops forecasts and raises revenue outlook as Sanofi collaboration progresses - Yahoo Finance

Yahoo Finance - Aug 06, 2026

Sanofi asked to change Dupixent ads after Galderma challenge - Fierce Pharma

Fierce Pharma - Aug 06, 2026

Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’ - BioSpace

BioSpace - Aug 06, 2026

Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey - Fierce Biotech

Fierce Biotech - Aug 05, 2026

Popular insulin product enters shortage as other pens leave market - STAT

STAT - Jul 23, 2026

Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues - Fierce Biotech

Fierce Biotech - Jul 30, 2026

Antipodes Exited Sanofi (SNY) After Repeated Pipeline Setbacks - Yahoo Finance

Yahoo Finance - Aug 06, 2026

Sanofi drug pipeline worries, Dupixent dependence shake shares - Reuters

Reuters - Jul 30, 2026

Sanofi Pauses Phase 2 Trial of Monoclonal Antibody SAR445399 in Chronic Lung Disease - BioPharm International

BioPharm International - Aug 06, 2026

Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline - WSJ

WSJ - Jul 30, 2026

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs - BioPharma Dive

BioPharma Dive - Jul 31, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment